ALGS
Aligos Therapeutics, Inc.Company with tickers: ALGS
CIK
1799448
CUSIP
01626L204
Shares Outstanding
5,388,223
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $2,830,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $29,759,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $23,352,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-26,929,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-23,040,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-2.21 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-2.21 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |